EUVIMEDEUVIMED entdecken
Editorial

Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study

Tsunenori Kondo iD

International Journal of Urology · 2026-05 · 33 (5)

DOI: 10.1111/iju.70489 ↗

Kurz gefasst

Editorial in der Zeitschrift International Journal of Urology, online erschienen am 30.04.2026. Verfasst von Tsunenori Kondo. Beteiligte Einrichtung: Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan. Die Arbeit nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Renal cell carcinomakidney function testsnephrectomyorgan sparing treatmentpostoperative complications

Autor:innen und Institutionen

  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.

ORCID-Profile: Tsunenori Kondo

Zitieren

APA

Kondo, T. (2026). Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70489

Vancouver

Kondo T. Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70489

BibTeX
@article{Kondo2026,
  author = {Kondo, Tsunenori},
  title = {Editorial Comment to Real‐World Effectiveness and Safety of Pembrolizumab–Lenvatinib Versus Axitinib‐Based Regimens in Metastatic Clear Cell Renal Cell Carcinoma: A Multicenter Retrospective Study},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {5},
  doi = {10.1111/iju.70489}
}
Kostenlos starten →